Entering text into the input field will update the search result below

Dosing underway in Arrowhead Pharma's mid-stage study of ARO-APOC3 in severe hypertriglyceridemia

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, an investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG).
  • A total of ~300 participants will be

Recommended For You

About ARWR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ARWR--
Arrowhead Pharmaceuticals, Inc.